Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Ladjevardi, Cecilia Olsson; Koliadi, Anthoula; Rydén, Viktoria; El‐Naggar, Ali Inan; Digkas, Evangelos; Valachis, Antonios; Ullenhag, Gustav

doi:10.1002/cam4.6013

Cited by 3 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, many studies did not find a higher risk for development of IRAEs in older patients ( 31 – 34 ), but conflicting results exist ( 35 ). In a previous study from our research group, we found that a simplified frailty score based on PS, age and comorbidity expressed as Charlson Comorbidity Index (CCI) could predict development of all grade and multiple IRAEs, whereas age, CCI or PS did not separately predict increased risk for development of IRAEs ( 36 ). Although not supported by our adjusted analyses, another potential explanation of the association between PS and the risk of IRAEs might be more related to the line of treatment rather than the PS per se.…”

Section: Discussionmentioning

confidence: 88%

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Olsson Ladjevardi,

Koliadi,

Rydén

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

IntroductionCheckpoint inhibitors (CPI) are widely used in cancer treatment with a potential of causing immune-related adverse events (IRAEs). Several studies have reported a positive correlation between development of IRAEs and improved survival outcome. However, few studies have focused on the potential role of multiple IRAEs on treatment effectiveness. This study aimed at investigating the association between multiple IRAEs and treatment effectiveness in terms of progression-free survival (PFS) and overall survival (OS) in advanced cancer patients.MethodsWe performed a retrospective cohort study at three Swedish centers. All patients (n=600) treated with PD-L1 or PD-1 inhibitor, in monotherapy or in combination for advanced cancer between January 2017 and December 2021 were included. Multiple IRAEs were defined as IRAEs involving more than one organ system either simultaneously or sequentially. Time-depending Cox-regression model to mitigate the risk for immortal time bias (ITB) was applied.ResultsThe major tumor types were non-small cell lung cancer (205 patients; 34.2%) and malignant melanoma (196 patients; 32.7%). Of all patients,32.8% developed single IRAE and 16.2% multiple IRAEs. Patients with multiple IRAEs showed significantly improved PFS (Hazard Ratio, HR=0.78 95% Confidence Interval, CI: 0.57–0.98) and OS (HR=0.65 95% CI: 0.44–0.95) compared to patients with single IRAE or no IRAE (HR=0.46 95% CI:0.34–0.62 for PFS vs HR=0.41 95% CI: 0.28-0.60 for OS).ConclusionIn conclusion, our data supports a stronger association between development of multiple as opposed to single IRAEs and clinical effectiveness in advanced cancer patients treated with CPIs.

show abstract

Section: Discussionmentioning

confidence: 88%

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Olsson Ladjevardi,

Koliadi,

Rydén

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events

Onur,

Mutlu,

Sertesen

et al. 2024

Immunotherapy

View full text Add to dashboard Cite

Aims: Our study aimed to evaluate the effectiveness of the Charlson Comorbidity Index (CCI) in predicting immune-related adverse events (irAEs) in solid tumor patients receiving immunotherapy. Patients & methods/materials: The CCI score at the time of initiation of immunotherapy was calculated in 164 solid tumor patients receiving immunotherapy and the correlation between the CCI score and immune toxicity was evaluated. Results: A significant relationship was found between CCI score and irAEs in lung cancer and renal cell cancer patients. In malignant melanoma, no significant relationship was found between the CCI score and the occurrence of irAEs. Conclusion: We argue that CCI can be used to predict irAEs, but we believe that a specific comorbidity index that includes autoimmune diseases should be developed.

show abstract

Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 3 publications

References 42 publications

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Predicting immune‐related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events

Contact Info

Product

Resources

About